medigraphic.com
ISSN 0326-3428 (Print)
Órgano de difusión científica de la Asociación Nefrológica de Buenos Aires

2024, Number 2

<< Back Next >>

Rev Nefrol Dial Traspl 2024; 44 (2)

Effects of AGLP1 in patients with diabetic kidney disease regarding renal prognosis

González MMÁ, López-González GJD, Mañero RC, Seguí RJM

Language: Spanish
References: 17
Page: 80-90
PDF size: 306.98 Kb.


ABSTRACT

Nowadays, there are multiple families of drugs for treating diabetes mellitus type 2, each of which has different therapeutic targets, highlighting the GLP1 receptor agonists (aGLP1). The main objective of this project was to study the effect of GLP1 receptor agonists in patients with diabetic kidney disease concerning renal prognosis. A historical cohort study, in which a group of patients with diabetic kidney disease whose treatment includes aGLP1 was compared to another group of patients with the same underlying disease whose treatment of diabetes mellitus type 2 does not include aGLP1. In the results, we observed that the presence of aGLP1 in the treatment supposes a RR of 0.057 (CI 0.008-0.394) compared with the group without aGLP1 (RR 17.55, CI 2.537-121.383) concerning the production of a deterioration of the glomerular filtration rate (GFR) >20%; as well as a RR of 0.285 (CI 0.126- 0.645) comparing the treatment group without aGLP1 (RR 3.51, CI 1.551- 7.942) with the increase in albuminuria >10%. In short, GLP1 agonists present benefits not only in glycemic control and cardiovascular risk but also with renal prognosis independently.


REFERENCES

  1. Saran R, Robinson B, Abbott KC, Agodoa LY,Albertus P, Ayanian J, Balkrishnan R, . US Renal DataSystem 2016 Annual Data Report: Epidemiology ofKidney Disease in the United States. Am J KidneyDis. 2017 Mar;69(3 Suppl 1):A7-A8.

  2. Wu B, Bell K; Stanford A et al. Understanding CKDamong patients with T2DM: prevalence, temporaltrends, and treatment patterns-NHANES 2007-2012. BMJ Open Diabetes Res Care. 2016;4:e000154.Doi: 10.1136/bmjdrc-2015-000154.

  3. Scheen AJ. Effects of glucose-lowering agentson surrogate endpoints and hard clinical renaloutcomes in patients with type 2 diabetes.Diabetes Metab. 2019;45:110-121. Doi: 10.1016/j.diabet.2018.10.003.

  4. Nauck, M.A.; Homberger, E.; Siegel, E.G., Allen,R.C.; Eaton, R.P.; Ebert, R.; Creutzfeldt, W. Incretineffects of increasing glucose loads in man calculatedfrom venous insulin and C-peptide responses. J.Clin. Endocrinol. Metab. 1986, 63, 492–498. Doi:10.1210/jcem-63-2-492.

  5. Holst, J.J. The physiology of glucagon-like peptide1. Physiol. Rev. 2007, 87, 1409–1439. Doi: 10.1152/physrev.00034.2006.

  6. Boer, G.A.; Holst, J.J. Incretin Hormones and Type2 Diabetes-Mechanistic Insights and TherapeuticApproaches. Biology 2020,9, 473. Doi: 10.3390/biology9120473.

  7. Worthington, J.J.; Reimann, F.; Gribble, F.M.Enteroendocrine cells-sensory sentinels of theintestinal environment and orchestrators of mucosalimmunity. Mucosal Immunol. 2018, 11, 3–20. Doi:10.1038/mi.2017.73.

  8. Bettge K; Kahle M; Abd El Aziz MS; Meier JJ;Nauck MA. Occurrence of nausea, vomiting anddiarrhoea reported as adverse events in clinicaltrials studying glucagon-like peptide-1 receptoragonists: a systematic analysis of published clinicaltrials. Diabetes Obes Metab. 2017;19:336-347. Doi:10.1111/dom.12824.

  9. Potts JE; Gray LJ; Brady EM; Khunti K; Davies MJ;Bodicoat DH. The effect of glucagon-like peptide 1receptor agonists on weight loss in type 2 diabetes: asystematic review and mixed treatment comparisonmeta-analysis. PLoS One. 2015 Jun 29;10(6):e0126769. Doi: 10.1371/journal.pone.0126769.

  10. Madsbad, S. Review of head-to-head comparisonsof glucagon-like peptide-1 receptor agonists.Diabetes Obes. Metab. 2016,18, 317–332. Doi:10.1111/dom.12596.

  11. Buse J.B; Rosenstock, J; Sesti, G; Schmidt W.E;Montanya, E; Brett J.H et al. LEAD-6 StudyGroup. Liraglutide once a day versus exenatide twicea day for type 2 diabetes: A 26-week randomised,parallel-group, multinational, open-label trial(LEAD-6). Lancet 2009, 374, 39–47. Doi: 10.1016/S0140-6736(09)60659-0.

  12. Marso, S.P.; Daniels, G.H.; Brown-Frandsen, K.;Kristensen, P.; Mann, J.F.; Nauck, M.A.; et al.LEADER Steering Committee; LEADER TrialInvestigators. Liraglutide and CardiovascularOutcomes in Type 2 Diabetes. N. Engl. J. Med. 2016,375, 311–322. Doi: 10.1056/NEJMoa1603827.

  13. Marso, S.P.; Bain, S.C.; Consoli, A.; Eliaschewitz,F.G.; Jódar, E.; Leiter, L.A.; et al. SUSTAIN-6Investigators. Semaglutide and CardiovascularOutcomes in Patients with Type 2 Diabetes. N.Engl. J. Med. 2016, 375, 1834–1844. Doi: 10.1056/NEJMoa1607141.

  14. Gerstein HC; Colhoun HM; Dagenais GR etal. Dulaglutide and cardiovascular outcomesin type 2 diabetes (REWIND): a double-blind,randomised placebo-controlled trial. Lancet. 2019Jul 13;394(10193):121-130. doi: 10.1016/S0140-6736(19)31149-3

  15. Skov J. Effects of GLP-1 in the kidney. Rev EndocrMetab Disord. 2014;15:197-207. Doi: 10.1007/s11154-014-9287-7.

  16. Koska J; Sands M; Burciu C; D’Souza KM;Raravikar K et al. Exenatide protects againstglucoseand lipid-induced endothelial dysfunction:Evidence for direct vasodilation effect of glp-1receptor agonists in humans. Diabetes 2015, 64:2624-2635. Doi: 10.2337/db14-0976.

  17. Ampudia-Blasco F.J.; Calvo Gómez C.; CosClaramunt X.; García Alegría J.; Jódar Gimeno E.et al. Liraglutide in the treatment of type 2 diabetes:recommendations for better patients’ selectionfrom a multidisciplinary approach. Avances enDiabetología. 2010; 26:226-34. Doi:10.1016/S1134-3230(10)64003-3.




2020     |     www.medigraphic.com